Online inquiry

IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4670MR)

This product GTTS-WQ4670MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4670MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6109MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ10973MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ6254MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ191MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ349MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ11424MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ7842MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ9371MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW